NovMetaPharma Co., Ltd. (XKON:229500)
South Korea · Delayed Price · Currency is KRW 8,080.00
-320.00 (-3.81%)
At close: Jun 30, 2026
NovMetaPharma Market Cap
NovMetaPharma has a market cap or net worth of 103.76 billion as of June 30, 2026. Its market cap has increased by 12.74% in one year.
Market Cap
103.76B
Enterprise Value
n/a
Revenue
1.30B
Ranking
n/a
PE Ratio
67.33
Stock Price
8,080.00
Market Cap Chart
Since April 5, 2017, NovMetaPharma's market cap has increased from 74.59B to 103.76B, an increase of 39.10%. That is a compound annual growth rate of 3.64%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 30, 2026 | 103.76B | -36.61% |
| Dec 30, 2025 | 163.69B | 187.16% |
| Dec 30, 2024 | 57.00B | -46.33% |
| Dec 29, 2022 | 106.21B | -45.89% |
| Dec 30, 2021 | 196.29B | -9.50% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2017 | Upgrade Pro | Upgrade Pro |
| Apr 5, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Genome & Company | 161.29B |
| Bio Solution | 152.25B |
| Prestige Biologics | 151.23B |
| ISU Abxis | 129.26B |
| ViGenCell | 123.61B |
| TiumBio | 110.69B |
| Cell Biotech | 102.66B |
| CORESTEMCHEMON | 88.19B |